The ACRF Department of Cancer Biology and Therapeutics uses the latest 'omics' technologies combined with classic biochemistry, cell biology, immunology and clinically relevant transgenic models of cancer to provide new knowledge of the fundamental mechanisms driving malignant transformation and metastasis. Through strategic alliances with industry and pharmaceutical companies, we are translating these findings into new therapeutics for the treatment of cancer. Work undertaken in this department has led to novel drugs in Phase I, II and III clinical trials for the treatment of both solid and hematologic malignancies. Our integrated research and training environment focuses on, but is not limited to, the following areas:

  • Targeting epigenetic modifiers and transcription factors for the treatment of hematologic and solid tumours.
  • Developing novel anti-cancer treatments that inhibit tumour angiogenesis and metastasis and identifying unique approaches to boosting anti-tumour immunity.
  • Repurposing existing antiretroviral drugs as anticancer agents for metastatic breast cancer therapy.
  • Use of gene editing techniques to develop new models of B cell lymphoma to understand the genesis and heterogeneity of this cancer and to develop novel therapeutic drugs.
  • Development of novel therapeutic approaches to processes that are fundamental to cancer cell growth – metabolism and ribosome biogenesis and to test the ability of these drugs to synergise with standard chemotherapies and overcome drug resistance in a broad range of cancers.
  • Investigating the role of platelets, neutrophils and other vascular cells in contributing to a tumour vascular environment, underpinning tumour metastasis and cancer-related thrombosis.